Symbols

AXGN

Axogen·NASDAQ

--(--)

Signals Analysis

Bullish signal 4

Bearish signal 1

Consensus Rating "Buy"

Ample Liquidity

High Gross Profit Margin

Significant Net Income Decline

EPS Beats Expectation

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About AXGN

Axogen, Inc.

A global leader in developing innovative surgical solutions for peripheral nerve injuries

Industry

Healthcare Equipment and Supplies

Established Date

Listing Date

08/09/2013

Exchange

NASDAQ Stock Exchange

Full-time Employees

622

Fiscal Year Ends

12-31

Website

www.axogeninc.com

Security Type

Common stock

Office address

13631 Progress Blvd. , Suite 400 Alachua , FL 32615

Business

Introduction

Axogen, Inc., was founded in Minnesota in 1977. The company is a leading company specializing in the science, development and commercialization of peripheral nerve regeneration and repair technologies. The company is keen to provide patients with peripheral nerve injury with the opportunity to restore nerve function and quality of life. The company provides innovative, clinically proven, cost-effective restorative solutions for surgeons and healthcare providers.

Company Financials

EPS

AXGN has released its 2025 Q4 earnings. EPS was reported at 0.07, versus the expected 0.06, beating expectations. The chart below visualizes how AXGN has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

AXGN has released its 2025 Q4 earnings report, with revenue of 59.90M, reflecting a YoY change of 21.25%, and net profit of -13.16M, showing a YoY change of -3023.56%. The Sankey diagram below clearly presents AXGN's revenue sources and cost distribution.